<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Nycomed News RSS feed</title><link>http://www.nycomed.com/media/</link><description>media</description><language>en</language><image><url>http://www.nycomed.com/~/media/Countries/www_nycomed_com/Settings/img_logo.ashx?20100422T1216486111</url><title>Nycomed News RSS feed</title><link>http://www.nycomed.com/media/</link></image><atom:link href="http://www.nycomed.com/media/?p=rss" rel="self" type="application/rss+xml" /><pubDate>Wed, 18 Jan 2012 09:13:44 GMT</pubDate><lastBuildDate>Wed, 18 Jan 2012 09:13:44 GMT</lastBuildDate><item><title>Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth</title><link>http://www.nycomed.com/media/news-releases/2012/takeda-announces-strategic-measures-to-achieve-efficiencies-for-long-term-growth/</link><description><![CDATA[
		
      OSAKA, Japan, January 18, 2012 - Takeda Pharmaceutical Company Limited (“Takeda”, TSE: 4502) announced today strategic measures to better align its global workforce and consolidate site operations in order to integrate legacy Nycomed operations, strengthen its presence in more than 70 countries, adapt to changing market conditions and maintain a focus on growth through innovation and culture, as outlined in its 2011-2013 Mid-Range Plan (MRP). 
The measures support both the execution of the company's strategy and the integration targets announced last year. They would also bring further efficiencies to the organization to sustain medium and long-term growth targets starting in fiscal 2015. The company will align Nycomed’s former operation structures and processes with the Takeda global headquarters in Japan and the newly defined organizations of the Chief Commercial Officer - which is headquartered in Zurich, Switzerland - and Chief Medical &amp;amp; Scientific Officer - which is headquartered in Deerfield, Illinois - and its expanded affiliate network worldwide.
“The combination of Takeda and Nycomed, which we acquired on September 30, 2011, brought together Takeda’s strong presence in the Japanese and U.S. markets with the legacy Nycomed business infrastructure in Europe and high-growth emerging markets,” said Yasuchika Hasegawa, President &amp;amp; CEO, Takeda Pharmaceutical Company Limited. “While our combined operations in more than 70 countries are more complementary than overlapping, there are a number of areas where we will need to make changes to ensure efficient and flexible operations moving forward.” 
Takeda will secure a sustainable future by maximizing the synergies of the steady integration of Takeda and Nycomed, such as the sales expansion of Takeda’s product pipeline utilizing Nycomed’s strong sales platforms in Europe and emerging countries. 
To meet the needs of the market, Takeda will also shift from a product portfolio centered on mature, high selling products to a more diverse portfolio focused on new products. The combined company has an active commercial presence in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.
Takeda also plans to consolidate its R&amp;amp;D sites to ensure ongoing support for all marketed products and support development and global registration of new products throughout the combined footprint. Takeda will invest strongly in R&amp;amp;D focused on core therapeutic areas, while effectively deploying both internal and external resources to create innovative drugs and transform treatment paradigms. The integrated R&amp;amp;D organization aims to support Takeda’s global vision of bringing innovative products to address patients’ needs by maximizing efficiency, driving standardization, optimizing resource utilization and driving productivity.&amp;nbsp;&amp;nbsp; 
To meet its goals, Takeda plans the consolidation of a number of sites and functions, including the potential merger or liquidation of subsidiaries mainly in Europe, and a reduction of workforce in the United States, primarily within Takeda Pharmaceuticals North America. The necessary cost for this plan is estimated approximately Yen 70 billion in total during fiscal 2011 - 2015. During this period, Takeda will achieve cost synergies of approximately Yen 200 billion. The cost synergy in Europe estimated in fiscal 2014 is now Yen 40 billion which is 10 billion greater than the original forecast announced in May 2011. Takeda plans a reduction of the Takeda global workforce by approximately 2,800 (2,100 mainly in Europe and 700 in the U.S.) positions by the end of fiscal 2015 across the functions of R&amp;amp;D, commercial, operations and G&amp;amp;A.
Employees affected by the measures will be offered appropriate guidance and support in accordance with Takeda’s corporate values and applicable local practices, policies and requirements.
The financial impact of this plan within fiscal 2011 ending March 2012 is estimated at Yen 35 billion downward in income, and the revised forecast of Takeda’s consolidated financial statements, including these strategic measures and other factors, will be disclosed upon fiscal 2011 3Q earnings release announcement scheduled on the 1st February 2012. The updates for progress of consolidation of sites and functions will be announced in an appropriate and timely manner.
These strategic measures and plans announced today are subject to appropriate information and consultation processes with affected employees and their representatives in accordance with applicable national laws on a country by country basis, which commence today.
About Takeda Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.
Takeda’s Forward-looking statementsThis press release contains forward-looking statements. Forward-looking statements include statements regarding Takeda's plans, outlook, strategies, results for the future, and other statements that are not descriptions of historical facts. Forward-looking statements may be identified by the use of forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," “assume,” "continue," "seek," "pro forma," "potential," "target," "forecast," “guidance,” “outlook” or "intend" or other similar words or expressions of the negative thereof. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors are cautioned not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to, (1) the economic circumstances surrounding Takeda's business, including general economic conditions in Japan, the United States and worldwide; (2) competitive pressures and developments; (3) applicable laws and regulations; (4) the success or failure of product development programs; (5) actions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates in development; and (8) integration activities with acquired companies. 
The forward-looking statements contained in this press release speak only as of the date of this press release, and Takeda undertakes no obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If Takeda does update or correct one or more of these statements, investors and others should not conclude that Takeda will make additional updates or corrections.
&amp;nbsp;
]]></description><pubDate>Wed, 18 Jan 2012 09:13:44 GMT</pubDate><guid>http://www.nycomed.com/media/news-releases/2012/takeda-announces-strategic-measures-to-achieve-efficiencies-for-long-term-growth/</guid></item><item><title>Takeda and MSD mutually agree to end co-promotion agreement for Daxas</title><link>http://www.nycomed.com/media/news-releases/2011/takeda-and-msd-mutually-agree-to-end-co-promotion-agreement-for-daxas/</link><description><![CDATA[
		
				Zurich, Switzerland, December 22, 2011 -- Takeda Pharmaceuticals International GmbH today announced that it has reached a mutual agreement with Merck &amp;amp; Co., Inc. (based in Whitehouse Station, New Jersey and known as MSD outside the USA and Canada) to terminate their co-promotion agreement for Daxas® (roflumilast) in certain European countries and Canada as of December 31, 2011. MSD will return the rights to Daxas® to Takeda in all countries covered by the agreement. 
Daxas® is a once-daily tablet for patients with chronic obstructive pulmonary disease (COPD).
As a result of the significant strengthening of the combined organization following Nycomed’s acquisition by Takeda Pharmaceutical Company Limited (“Takeda”) at the end of September 2011, Takeda will now use its own sales organization to market Daxas® in the seven territories covered by the original agreement, signed in April 2010. Further details were not disclosed.
About Roflumilast (Daxas®) 
Roflumilast(Daxas®) is an orally administered selective phosphodiesterase 4 (PDE4) enzyme inhibitor, which has been shown to inhibit COPD related inflammation with a novel mode of action. Daxas, a once-a-day tablet, is the first drug in a new class of treatment for severe COPD associated with chronic bronchitis and the first oral anti-inflammatory treatment specifically developed for COPD patients. It has received approval in several countries, including the European Union, US and Canada for the treatment of severe COPD associated with chronic bronchitis.
About Takeda Pharmaceuticals International GmbH &amp;nbsp;Takeda Pharmaceuticals International GmbH, headquartered in Zurich, is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As the largest pharmaceutical company in Japan and a leader in the global industry, Takeda’s mission is to strive toward better health for patients worldwide through leading innovation in medicine. It has a commercial presence covering more than 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China. Takeda is ranked 12th by global Rx sales, 14th in the BRIC countries and 18th in Europe. Takeda’s commercial presence mainly covers the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.&amp;nbsp;Additional information about Takeda is available through its corporate website, www.takeda.com. ]]></description><pubDate>Thu, 22 Dec 2011 07:15:03 GMT</pubDate><guid>http://www.nycomed.com/media/news-releases/2011/takeda-and-msd-mutually-agree-to-end-co-promotion-agreement-for-daxas/</guid></item><item><title>Steovess® accepted for national approvals in European Union</title><link>http://www.nycomed.com/media/news-releases/2011/steovess-accepted-for-national-approvals-in-european-union/</link><description><![CDATA[
		Zurich, Switzerland, December 20, 2011 - Takeda Pharmaceuticals International GmbH (“Takeda”) today announced that the European decentralised procedure (DCP) was positively concluded for Steovess® (formerly known as EX101), a once-a-week 70mg buffered effervescent alendronate for the treatment of post-menopausal osteoporosis.
The Company submitted its application for marketing authorization in multiple countries through the DCP on 17 September 2010, with the United Kingdom (MHRA) serving as its Reference Member State (RMS). Following its evaluation, the RMS and all Concerned Member States (CMS) reached consensus that Steovess® is approvable. The regulatory process will enter now into the national phase in which each of the member states shall adopt a national decision and grant national marketing authorizations. Pending those decisions, Takeda anticipates first launches in the second half of 2012. European approval will be used as the basis for submissions in key emerging markets.
Trevor Smith, Head of Europe and Canada said: “Osteoporosis affects more than 200 million people globally and its prevalence is expected to increase rapidly as the global population ages. Steovess® represents an important new treatment option for these patients, who often stop taking their medications because of the inconvenience associated with existing tablet forms of alendronate. Steovess® complements our existing osteoporosis offering and we believe it will be an important new treatment for patients with this debilitating disease in Europe and other key markets”.
Alendronate is a bisphosphonate which reduces the risk of vertebral and hip fractures in women suffering from post-menopausal osteoporosis. Steovess® is a unique once-weekly effervescent tablet, which, after being dissolved in water, delivers alendronate to the stomach in a proprietary buffered strawberry flavoured solution. With no tablet to swallow, a reduced volume to drink and no risk of a tablet getting stuck in the oesophagus, Steovess® aims to offer patients a more convenient dosage form, thereby improving compliance and adherence.
Steovess®, which will also be known as Avalent® or Binosto® in some countries, has been licensed from EffRx Pharmaceuticals SA of Lausanne, Switzerland. Under the agreement with EffRx, Takeda holds exclusive rights to develop, manufacture and commercialise the effervescent formulation of alendronate for the treatment of osteoporosis in all territories in the world except USA, Canada, and Japan.
Takeda has an established presence in the osteoporosis market through its existing portfolio. This includes Preotact® (full-length parathyroid hormone [PTH (1-84)]) for treatment of osteoporosis in post-menopausal women at high risk of fractures, and its broad Calcium D3 product range for those individuals who are unable to get enough calcium and vitamin D to ensure bone health and as a required adjunct to all osteoporosis treatments.
About Takeda Pharmaceuticals International GmbH Takeda Pharmaceuticals International GmbH, headquartered in Zurich, is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As the largest pharmaceutical company in Japan and a leader in the global industry, Takeda’s mission is to strive toward better health for patients worldwide through leading innovation in medicine. It has a commercial presence covering more than 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China. Takeda is ranked 12th by global Rx sales, 14th in the BRIC countries and 18th in Europe. Takeda is mainly focused on the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.
Additional information about Takeda is available through its corporate website, http://www.takeda.com. ]]></description><pubDate>Tue, 20 Dec 2011 07:07:32 GMT</pubDate><guid>http://www.nycomed.com/media/news-releases/2011/steovess-accepted-for-national-approvals-in-european-union/</guid></item><item><title>Takeda Appoints Jostein Davidsen Head of Emerging Markets</title><link>http://www.nycomed.com/media/news-releases/2011/takeda-appoints-jostein-davidsen-head-of-emerging-markets/</link><description><![CDATA[
		Nycomed, a Takeda Company, today announced that Jostein Davidsen has been appointed Head of Emerging Markets in addition to his current role as Area Head of Russia/CIS. He will report to Frank Morich, EVP, International Operations (Americas/Europe), Takeda Pharmaceuticals International, and CEO of Nycomed. The appointment is effective immediately. 
Nycomed’s presence in Emerging Markets was a key driver for Takeda to acquire Nycomed at the end of September 2011. These fast-growing markets are an important lever to achieve Takeda’s sustainable growth aspirations as outlined in the 2011-2013 Mid-Range-Plan. The Emerging Markets Region comprises Russia/CIS, Latin America, Middle East-Turkey-Africa, and South Asia.
“Jostein’s strong track record of leading Russia/CIS over the past 17 years makes him an ideal candidate for this position.” said Frank Morich, EVP, International Operations (Americas/Europe), Takeda Pharmaceuticals International and CEO, Nycomed. “His extensive knowledge of the industry, combined with vision and tenacity, has propelled Russia/CIS to become one of Nycomed’s top revenue contributors.”
Jostein Davidsen has been leading the legacy Nycomed Russia/CIS area since 1994. Since then, the region has grown into the company’s largest market. Today, Nycomed: a Takeda Company is among the top 10 companies in sales in Russia and all of the CIS pharmaceutical markets and has outpaced average market growth more than two times in the last decade. In 2010, Russia/CIS had total sales of €479 million, growing by 31% in local currencies. The company has established itself as a preferred partner for international pharmaceutical companies in Russia/CIS. Nycomed is investing in a pharmaceutical manufacturing facility in Yaroslavl, making it one of the first international companies in Russia to take such a step.
About Nycomed: a Takeda Company
Nycomed is a Takeda company since end of September 2011. Takeda is a research-based global company with its main focus on pharmaceuticals. The combined company has an active commercial presence in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management. 
Takeda’s traditional strengths in North America, Japan, and the rest of Asia, are now complemented by Nycomed’s position in Europe and the high growth emerging markets. The combined company has a presence in more than 70 countries worldwide, and ranked 12th by global Rx sales, 14th in the BRIC countries and 18th in Europe. 
About Takeda
As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com. &amp;nbsp;]]></description><pubDate>Mon, 17 Oct 2011 07:23:33 GMT</pubDate><guid>http://www.nycomed.com/media/news-releases/2011/takeda-appoints-jostein-davidsen-head-of-emerging-markets/</guid></item><item><title>Takeda completes acquisition and names new CEO of Nycomed </title><link>http://www.nycomed.com/media/news-releases/2011/takeda-completes-acquisition-and-names-new-ceo-of-nycomed/</link><description><![CDATA[
		
				OSAKA, Japan, September 30, 2011 – Takeda Pharmaceutical Company Limited (“Takeda”, TSE: 4502) announced it has completed its acquisition of Nycomed A/S (“Nycomed”) for 9.6 billion Euro on a cash-free, debt-free basis and made Nycomed a wholly owned subsidiary of Takeda effective the same day. Dr. Frank Morich has been named CEO of Nycomed in addition to his current role as Executive Vice President (EVP), International Operations (Americas/Europe), Takeda Pharmaceuticals International, Inc., a wholly owned subsidiary of Takeda America Holdings, Inc. &amp;nbsp;The transaction fits in with Takeda’s sustainable growth strategy outlined in its 2011–2013 Mid-Range Plan (MRP). Takeda has a strong presence in the Japanese and U.S. markets, while Nycomed has a significant business infrastructure in Europe and high-growth emerging markets that will enhance Takeda’s regulatory development expertise and commercialization capability. In addition, the acquisition will bring Takeda an immediate and stable increase in cash flow generated from annual revenue of more than 2.8 billion Euro from the acquired business. &amp;nbsp;“The combination of both organizations will strengthen Takeda’s performance during the 2011-2013 MRP period, and enable us to sustain medium and long-term growth targets starting in fiscal 2015 and extending into the next decade,” said Yasuchika Hasegawa, President &amp;amp; CEO of Takeda. “Partnering the two organizations will have complementary effects and further increase our potential to become a truly global pharmaceutical company.” &amp;nbsp;“I look forward to bringing Takeda and Nycomed together to ensure we can achieve enhanced revenue, growth and diversification, while maintaining the strong momentum of both companies,” said Frank Morich. “The combined company significantly broadens our coverage of the global pharmaceutical market to more than 70 countries, increasing our global Rx sales ranking to 12th and further strengthening our position in the industry.” &amp;nbsp;The combined company will have an active commercial presence in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management, as well as having a well-balanced presence in pharmaceutical markets of Japan, North America, Europe and Asia/Emerging Markets. 
&amp;nbsp;
The integration enhances the 1,260 billion yen of projected FY 2013 sales in 2011-13 MRP by more than 30 percent and improves the 280 billion yen of projected FY 2013 operating income (excluding special factors derived from business acquisition) in 2011-13 MRP by more than 40 percent. Takeda will now start preparation of the consolidated financial outlook for its fiscal 2011 ending March 31, 2012, and is planning to announce it upon announcement of its financial results of fiscal 2011 2Q scheduled in November.&amp;nbsp;
About Takeda 
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com
Takeda’s Forward-looking statements&amp;nbsp;
This press release contains forward-looking statements. Forward-looking statements include statements regarding Takeda's plans, outlook, strategies, results for the future, and other statements that are not descriptions of historical facts. Forward-looking statements may be identified by the use of forward-looking words such as may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," “assume,” "continue," "seek," "pro forma," "potential," "target," "forecast," “guidance,” “outlook” or "intend" or other similar words or expressions of the negative thereof. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors are cautioned not to unduly rely on such forward-looking statements. &amp;nbsp;Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to, (1) the economic circumstances surrounding Takeda's business, including general economic conditions in Japan, the United States and worldwide; (2) competitive pressures and developments; (3) applicable laws and regulations; (4) the success or failure of product development programs; (5) actions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates in development; and (8) integration activities with acquired companies.&amp;nbsp; &amp;nbsp;The forward-looking statements contained in this press release speak only as of the date of this press release, and Takeda undertakes no obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If Takeda does update or correct one or more of these statements, investors and others should not conclude that Takeda will make additional updates or corrections. ]]></description><pubDate>Fri, 30 Sep 2011 09:47:10 GMT</pubDate><guid>http://www.nycomed.com/media/news-releases/2011/takeda-completes-acquisition-and-names-new-ceo-of-nycomed/</guid></item><item><title>Nycomed and Almirall announce a licensing agreement for ebastine</title><link>http://www.nycomed.com/media/news-releases/2011/nycomed-and-almirall-announce-a-licensing-agreement-for-ebastine/</link><description><![CDATA[
		
Nycomed to take responsibility for sales, marketing and distribution of Kestine® (ebastine) in China, where it is already approved and reimbursed 
Kestine® will also be launched in Malaysia, Philippines, Singapore, Thailand and Indonesia, strengthening Nycomed’s and Almirall’s position in Asia Pacific through licensing of innovative brands 
With this agreement, Almirall extends the global reach of the product, present now in more than 30 countries worldwide
&amp;nbsp;
Nycomed and Almirall today announced that they have signed a licensing and supply agreement for Almirall’s R&amp;amp;D antihistamine ebastina, under the trademark Kestine®, indicated for allergic rhinitis and chronic idiopathic urticaria, in China and other key emerging markets. Under the terms of the agreement, Nycomed will have exclusive commercialisation rights for the existing Kestine® product in China. Additionally, Kestine® will be launched in Malaysia, Philippines, Singapore, Thailand and Indonesia, with Nycomed becoming marketing authorisation holder in these territories. Financial details of the agreement were not disclosed.Kestine® (ebastine) is a product developed by Almirall’s R&amp;amp;D and which to date has been marketed in more than 30 countries worldwide through the company’s own affiliates and licensees. Its efficacy and safety are backed by thorough, extensive research: over 100 clinical studies have been conducted on over 15,700 patients.Luciano Conde, Almirall’s Chief Operating Officer, commented: “We are very pleased to extend our collaboration with Nycomed to the Asia Pacific region. This agreement represents a step further in extending the global reach of ebastine to new patients and maximizing its value potential.”Guido Oelkers, Executive Vice President, Commercial Operations, said: “We are very pleased to have signed this license agreement to further expand our Asia Pacific product portfolio. Almirall’s Kestine is a high quality antihistamine which brings existing sales and potential for growth in China and further expansion in other key regional markets. Emerging markets continue to be our focus area for future growth.”Nycomed has one of the highest proportions of sales from emerging markets among major pharmaceutical companies. The company recently opened offices in China, South Korea, Indonesia, Malaysia and the Philippines, rapidly increasing its capabilities in the region through the repatriation of its own core brands and the licensing of innovative products from other companies. 
About Kestine
Kestine® (ebastine) is a product developed by Almirall’s R&amp;amp;D and which to date has been marketed in more than 30 countries worldwide through the company’s own affiliates and licensees.Ebastine is a second-generation non-sedating H1 receptor antagonist antihistamine that is administered once a day. It is prescribed for the treatment of allergic rhinitis and chronic idiopathic urticaria. In some countries, it is prescribed for improving the symptoms associated with mosquito bites and atopical dermatitis.Its efficacy and safety are backed by thorough, extensive research: over 100 clinical studies have been conducted on over 15,700 patients.
About Almirall
Almirall is an international pharmaceutical company based on innovation and committed to health. Headquartered in Barcelona, Spain, it researches, develops, manufactures and commercialises its own R&amp;amp;D and licensed drugs with the aim of improving people’s health and wellbeing.&amp;nbsp;&amp;nbsp;&amp;nbsp; Almirall focuses its research resources on therapeutic areas related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), gastrointestinal disorders, psoriasis and other dermatological conditions. Almirall’s products are currently present in over 70 countries while it has direct presence in Europe and Latin America through 12 affiliates.For further information please visit the website at: www.almirall.com 
About Nycomed
Nycomed is a privately owned global pharmaceutical company with a diversified portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC products completes the portfolio.Its R&amp;amp;D is structured around collaborations. In-licensing and expanding in emerging markets are cornerstones of the company's growth strategy.Nycomed employs 12,500 associates worldwide, and its products are sold in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, Latin America, Asia and the Middle East. In the US and Japan its products are available through best in class partners.Headquartered in Zurich, Switzerland, the company generated total sales of €3.2 billion in 2010 and an adjusted EBITDA of €851 million.]]></description><pubDate>Thu, 29 Sep 2011 05:58:58 GMT</pubDate><guid>http://www.nycomed.com/media/news-releases/2011/nycomed-and-almirall-announce-a-licensing-agreement-for-ebastine/</guid></item><item><title>New data analysis supports the use of Daxas</title><link>http://www.nycomed.com/media/news-releases/2011/new-data-analysis-supports-the-use-of-daxas/</link><description><![CDATA[
		
New data analysis presented at ERS 2011 supports the ability of roflumilast to shift COPD patients from the frequent to the more stable infrequent exacerbator state1&amp;nbsp;&amp;nbsp; 
Data support use of roflumilast to prevent exacerbations, which currently impose a substantial burden on patients and health-care systems worldwide2&amp;nbsp;
&amp;nbsp;
Nycomed today announced new findings to show that Daxas® (roflumilast) helps to prevent exacerbations in COPD patients of the ‘frequent exacerbator’ phenotype.1 The data, presented at the 2011 European Respiratory Society (ERS) Annual Congress in Amsterdam, 24 – 28 September, have important implications for the management of COPD in this patient population, who are at increased risk of disease progression compared with those who have no or infrequent exacerbations.2 Frequent exacerbations are of concern to a significant group of COPD patients, despite access to available therapy.&amp;nbsp;3 They are distressing for patients and lead to poorer health status and faster disease progression, imposing a substantial burden on patients.2&amp;nbsp; Exacerbations also significantly impact the functional ability of COPD patients – patients with frequent exacerbations reduce the time they spend outdoors at a faster rate compared with those with infrequent exacerbations and are more likely to become housebound.4 
Lead investigator Professor Jadwiga Wedzicha comments: “The results of our analysis are important because they show that the anti-inflammatory effects of roflumilast can help to reduce exacerbations in the ‘frequent exacerbator’ phenotype and this is clinically significant from both the patients’ and clinicians’ perspective. This ‘frequent exacerbator’ group show worse health status and faster disease progression than those who are ‘infrequent exacerbators’. Thus in this patient population, reducing exacerbations is a key treatment goal. We also need to be better at identifying these patients at risk by proactively asking patients about their exacerbation history, including previous worsening episodes treated with oral steroids and/or antibiotics or requiring admission to hospital.” 
The data presented at ERS 2011 are from a post-hoc pooled analysis of two one-year studies of more than 1,500 roflumilast-treated patients with severe COPD, chronic bronchitis and a history of exacerbations.1* Among patients identified as frequent exacerbators, treatment with roflumilast over a year lowered the risk for those remaining in the frequent exacerbator state by 20% as compared to placebo (RR=0.799, p=0.0148).1 Among patients identified as infrequent exacerbators, treatment with roflumilast over a year lowered the risk of becoming a frequent exacerbator by 23% as compared to placebo (RR=0.768, p=0.0018).1 Thus this analysis shows that roflumilast offers COPD patients an improvement in their exacerbations status by shifting patients from the frequent to the more stable infrequent exacerbator state.1 
Anders Ullman, Executive Vice President, Research and Development at Nycomed, comments: “These are important data, as they continue to reinforce the therapeutic value of roflumilast to reduce exacerbation frequency. COPD exacerbations are frightening and devastating to experience, and roflumilast provides added value to patients suffering from frequent exacerbations by helping them achieve a more stable disease state.”
Daxas is the first in a new class of treatment, phosphodiesterase 4 (PDE4) inhibitors, and has received approval in several countries, including the European Union, US and Canada for the treatment of severe COPD associated with chronic bronchitis. In the 2010 update of its COPD management guidelines, The Global Initiative for Chronic Obstructive Lung Disease (GOLD) included roflumilast as a new treatment option, acknowledging its principal action to reduce inflammation and the clinical implications in terms of exacerbation reduction in GOLD stage III and IV COPD patients.5
* Notes to editorsAmong roflumilast-treated frequent exacerbators (n=413), 32.0% still had frequent exacerbations at year 1 vs. 40.8% of placebo-treated patients (n=417; RR=0.799, p=0.0148).1 Among infrequent exacerbators, 17.5% of roflumilast-treated patients (n=1124) had ≥2 exacerbations at year 1 vs. 22.9% of placebo-treated patients (n=1137; RR=0.768, p=0.0018).1 
About Daxas® (roflumilast)
Daxas (roflumilast) is an orally administered selective phosphodiesterase 4 (PDE4) enzyme inhibitor, which has been shown to inhibit COPD related inflammation with a novel mode of action.6 Daxas, a once-a-day tablet, is the first drug in a new class of treatment for severe COPD associated with chronic bronchitis and the first oral anti-inflammatory treatment specifically developed for COPD patients. 
Four large randomized placebo controlled trials have shown that roflumilast significantly reduces exacerbations and improves lung function when added to long acting bronchodilators.7,8 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) included roflumilast as a new treatment option in the 2010 update of its COPD management guidelines, acknowledging its principal action to reduce inflammation and the clinical implications in terms of exacerbation reduction in GOLD stage III and IV COPD patients.5
Daxas is generally well tolerated. In clinical COPD trials involving 12,000 patients, the most commonly reported adverse reactions were diarrhoea (5.9%), weight decreased (3.4%), nausea (2.9%), abdominal pain (1.9%) and headache (1.7%). The majority of these adverse reactions were mild or moderate. These adverse reactions mainly occurred within the first weeks of therapy and mostly resolved on continued treatment.9 
Other pharmacological treatment for COPD patients includes the use of inhaled bronchodilators and inhaled corticosteroids.
About COPD
COPD remains a significant area of unmet medical need. It is a progressive and irreversible lung disease resulting in difficulty in breathing. The disease is characterised by severe episodes of worsening, called exacerbations or lung attacks. According to World Health Organization (WHO) estimates, 80 million people have moderate to severe COPD worldwide. More than 3 million people died of COPD in 2005, which corresponds to 5% of all deaths globally. The WHO predicts that total deaths from COPD could increase by more than 30% in the next 10 years unless urgent action is taken to reduce the underlying risk factors, especially smoking.&amp;nbsp;www.who.int/respiratory/copd/burden/en/index.html
About Nycomed
Nycomed is a privately owned global pharmaceutical company with a diversified portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC products completes the portfolio.
Its R&amp;amp;D is structured around collaborations. In-licensing and expanding in emerging markets are cornerstones of the company's growth strategy.
Nycomed employs 12,500 associates worldwide, and its products are sold in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, Latin America, Asia and the Middle East. In the US and Japan its products are available through best in class partners.
Headquartered in Zurich, Switzerland, the company generated total sales of € 3.2 billion in 2010 and an adjusted EBITDA of € 851 million.
&amp;nbsp;
_______________________________________
(1) Wedzicha JA et al. Efficacy of roflumilast in the frequent exacerbation COPD phenotype. Presented at 2011 European Respiratory Society Annual Meeting, Poster Discussion : Biomarkers and exacerbations of asthma and COPD, Tuesday 28 September 2011, 8:30-10:30, P3355.(2) Wedzicha JA and Seemungal TAR. COPD exacerbations: defining their cause and prevention. Lancet 2007; 370: 786–96(3) Hurst HR et al. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease N Engl J Med. 2010;363:1128- 38 .&amp;nbsp;(4) Donaldson GC, et al. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171:446-452.(5) From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. Available from www.goldcopd.org/ (6) Hatzelmann A, et al. The preclinical pharmacology of roflumilast – a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease, Pulm Pharm Ther 2010;23:235–256.(7) Calverley PMA, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685–94.(8) Fabbri LM, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695–703.(9)EU Summary of Product Characteristics, Daxas®, May 2011 
&amp;nbsp;]]></description><pubDate>Sat, 24 Sep 2011 22:00:00 GMT</pubDate><guid>http://www.nycomed.com/media/news-releases/2011/new-data-analysis-supports-the-use-of-daxas/</guid></item><item><title>Nycomed and Norgine sign a Licence Agreement for MOVIPREP in Russia/CIS</title><link>http://www.nycomed.com/media/news-releases/2011/nycomed-and-norgine-sign-a-licence-agreement-for-moviprep/</link><description><![CDATA[
		
				Nycomed and Norgine, a European specialty pharmaceutical company,&amp;nbsp; today announced that they have entered into a licensing agreement that gives Nycomed the exclusive rights to commercialise MOVIPREP, the worlds leading bowel cleansing brand, in Russia, Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Mongolia, Tajikistan, Turkmenistan, Ukraine, and Uzbekistan.
				Moviprep is an osmotic laxative for bowel cleansing prior to any clinical procedure requiring a clean bowel, such as colonoscopy. MOVIPREP will be subject to regulatory review and approval and Nycomed will conduct the necessary steps for approval. Financial details of the agreement were not disclosed.We are very pleased to further expand our recently established gastrointestinal product portfolio with MOVIPREP,” said Jostein Davidson, Senior Vice President, Nycomed Group, and President, Nycomed Russia-CIS.&amp;nbsp; “MOVIPREP has proven to be the preferred choice for bowel preparation in EU and Nycomed is proud to make this product a success in Russia/CIS improving quality of life of millions of patients.”Norgine’s CEO, Peter Stein said: “This is an important agreement for Norgine as it will mark our entry into this fast developing market.&amp;nbsp; We look forward to working with Nycomed to capitalise on their extensive sales and distribution network to help realise MOVIPREP’s potential in the CIS."MOVIPREP is marketed by Norgine through its own Sales and Marketing organisation and by Salix Pharmaceuticals in the USA, by Medical Futures in Canada, by PharmaSwiss in Central and Eastern Europe and is under development with Ajinomoto in Japan.
About Norgine
Norgine is an independent, successful European speciality pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2010, Norgine’s net product sales were €258 million. The Company employs over 1,200 people. Norgine’s focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology and supportive care. The Company currently markets a range of products in various markets in its key therapeutic areas e.g., MOVICOL® for the treatment of constipation and faecal impaction, MOVIPREP® a bowel cleansing preparation, KLEAN-PREP® for bowel preparation prior to colonoscopy, XIFAXAN® for the treatment of travellers diarrhoea and ORAMORPH® for the treatment of moderate to severe pain associated with cancer. Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, UK and Dreux, France.
About Nycomed
Nycomed is a privately owned global pharmaceutical company with a diversified portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC products completes the portfolio.
Its R&amp;amp;D is structured around collaborations. In-licensing and expanding in emerging markets are cornerstones of the company's growth strategy.
Nycomed employs 12,500 associates worldwide, and its products are sold in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, Latin America, Asia and the Middle East. In the US and Japan its products are available through best in class partners.
Headquartered in Zurich, Switzerland, the company generated total sales of € 3.2 billion in 2010 and an adjusted EBITDA of € 851 million.
&amp;nbsp;]]></description><pubDate>Mon, 22 Aug 2011 07:13:18 GMT</pubDate><guid>http://www.nycomed.com/media/news-releases/2011/nycomed-and-norgine-sign-a-licence-agreement-for-moviprep/</guid></item><item><title>Nycomed reports double-digit growth across emerging markets in second quarter 2011</title><link>http://www.nycomed.com/media/news-releases/2011/nycomed-reports-double-digit-growth-across-emerging-markets-in-second-quarter-2011/</link><description><![CDATA[
		
Strong performance in emerging markets helped offset challenging conditions in mature European markets; emerging markets accounted for 46.3% of Q2 turnover 
Total net turnover steady at €786.2 million (+2.4% in local currencies), with emerging markets growing 23.5% in local currencies 
Adjusted Q2 EBITDA down 4.5% at €188.6 million (+2.2% in local currencies); H1 EBITDA €501.0 million, up 16.4%, including one-time Forest Laboratories payment (+16.5% in local currencies) 
Partnerships progressing: Transfer of marketing authorisation approvals in Asia-Pacific for Bonviva® (Ibandronate) from Roche completed and Turkish portfolio strengthened; commercialization agreement with Allmirall for roflumilast in Spain; Collaboration signed with Orion on Easyhaler® combination products 
NDA submitted in US for ciclesonide nasal aerosol HFA formulation by US partner Sunovion; Instanyl® single-dose spray approved in Europe 
Agreement with Takeda to acquire Nycomed announced in May 2011, subject to antitrust clearance 
&amp;nbsp;
The financial results reported in this press release are related to Nycomed S.C.A. SICAR and comprise all of the Nycomed Group’s operations. The full interim report is available at&amp;nbsp;Investors 
Nycomed today announced results for the second quarter of 2011, achieving double digit growth across emerging markets. Good progress was made in Key Products, particularly in the respiratory area. Following U.S. approval of Daliresp™ for the treatment of COPD earlier this year, Nycomed's partner Forest Laboratories introduced the product to the market and is preparing a full launch in the third quarter. In May, Nycomed agreed to be acquired by Takeda, subject to antitrust clearance, creating a truly global pharmaceutical business equipped to meet the needs of patients, doctors and healthcare providers. 
Net turnover in the second quarter was stable compared with the second quarter 2010, up 2.4% in local currencies to €786.2 million. Strong growth was achieved in Asia-Pacific, Africa and Middle East (+80.8% in Q2, +68.8% in H1 in local currencies), Russia/CIS (+10.9% in Q2, +20.5% in H1 in local currencies) and Latin America (+5.5% in Q2, +10.0% in H1 in local currencies) continued to grow, offsetting the challenging conditions in the US and Western Europe. 
Commenting on the company’s second quarter performance, Nycomed CEO Håkan Björklund said: “We again saw the success of our increasing focus on emerging markets in the second quarter, with strong performances in areas such as Asia, Middle East and Latin America helping to offset anticipated declines in some of the more mature markets of Western Europe and the US.
We look forward to closing the agreement with Takeda for the acquisition of Nycomed announced in May and to creating a truly global pharmaceutical business equipped to meet the needs of patients, doctors and healthcare providers. Nycomed ends the first half of 2011 in excellent shape and looks forward to an even brighter future.”
Key figures




&amp;nbsp;
Q2 2011(€m)
Q2 2010(€m)
Change&amp;nbsp;&amp;nbsp;&amp;nbsp;
H1 2011(€m)
H1 2010(€m)
Change&amp;nbsp;&amp;nbsp;&amp;nbsp;

Net turnover
786.2
786.5
0.0%2.4%(1)
1,710.0
1,562.9
9.4%8.9%(1)

Gross profitMargin
549.969.9%
552.170.2%
-0.4%
1,221.471.4%
1,100.270.4%
11.0%

Operating profit (EBIT)
45.8
16.1
184.5%
213.3
57.6
270.3%

EBITDAMargin
175.822.4%
188.524.0%
-6.7%
469.827.5%
401.025.7%
17.2%

Adjusted EBITDA&amp;nbsp;Margin
188.624.0%
197.425.1%
4.5%2.2%(1)
501.029.3%
430.427.5%
16.4%16.5%(1)

(1)&amp;nbsp;In local currencies 
About Nycomed
Nycomed is a privately owned global pharmaceutical company with a diversified portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC products completes the portfolio.
Its R&amp;amp;D is structured around collaborations. In-licensing and expanding in emerging markets are cornerstones of the company's growth strategy.Nycomed employs 12,500 associates worldwide, and its products are sold in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, Latin America, Asia and the Middle East. In the US and Japan its products are available through best in class partners.
Headquartered in Zurich, Switzerland, the company generated total sales of € 3.2 billion in 2010 and an adjusted EBITDA of € 851 million.]]></description><pubDate>Wed, 17 Aug 2011 06:47:39 GMT</pubDate><guid>http://www.nycomed.com/media/news-releases/2011/nycomed-reports-double-digit-growth-across-emerging-markets-in-second-quarter-2011/</guid></item><item><title>Nycomed and Orion Corporation to collaborate on Easyhaler® for asthma and COPD</title><link>http://www.nycomed.com/media/news-releases/2011/nycomed-and-orion-corporation-to-collaborate-on-easyhaler-for-asthma-and-copd/</link><description><![CDATA[
		
Companies to co-market Easyhaler® combination products in major European markets 
Nycomed to market Easyhaler® products in MENA under exclusive licensing agreement 
Significant strengthening of Nycomed’s fast-growing Respiratory portfolio
Nycomed announced today that it has entered into a collaboration agreement with Orion Corporation (Nasdaq OMX Helsinki: ORNAV and ORNBV) for the co-marketing of Easyhaler® combination products for the treatment of asthma and COPD in the major European countries and an exclusive license and distribution arrangement for the Middle East and North Africa region (MENA). Both companies will commercialise Easyhaler combination products under their own brands accompanied by the Easyhaler umbrella brand. The agreement covers Orion’s new Easyhaler combination products for treatment of asthma and COPD (chronic obstructive pulmonary disease). Orion is developing a budesonide-formoterol formulation that combines budesonide as an anti-inflammatory agent and formoterol as a long-acting bronchodilator. In addition, Orion has another Easyhaler® research programme in progress to develop a fluticasone-salmeterol formulation. In this formulation fluticasone acts as an anti-inflammatory agent and salmeterol acts as a long-acting bronchodilator. Both these combination products are included in the co-marketing agreement. Respiratory is a key strategic area for Nycomed, including the COPD treatment Daxas® (roflumilast), Alvesco® (ciclesonide) for asthma, and Omnaris® (ciclesonide) for allergic rhinitis. The collaboration with Nycomed reinforces Orion’s presence throughout Europe and is in line with Orion's strategy to strengthen its marketing position in Europe and the sales coverage through partnerships. The co-marketing area – in which both companies present their own product brands under the Easyhaler umbrella brand – covers the major European countries including Austria, the Benelux countries, France, Germany, Greece, Italy, Poland, Portugal, Spain and Switzerland. Orion will retain exclusive marketing rights for the Nordic countries, U.K. and Eastern Europe where the company is currently promoting single molecule Easyhaler products. Orion will exclusively manufacture the Easyhaler combination products covered by the agreement.Dr. Liisa Hurme, Senior Vice President of Orion’s Proprietary Products division, commented: “I am excited about the collaboration agreement and look forward to having such a strong partner focusing on the treatment of asthma and chronic obstructive pulmonary disease. The collaboration creates a momentum for Easyhaler products in Europe and strengthens Orion’s strategic objective to become a stronger player in the field of respiratory medication.” Guido Oelkers, Executive Vice President Commercial Operations, Nycomed, commented: “We are very pleased to have signed this collaboration agreement with Orion. We see great potential in these high quality Easyhaler products in major European countries and the MENA region. They will significantly enhance Nycomed's fast-growing Respiratory portfolio.” 
About Easyhaler®
Orion’s portfolio of proprietary products includes Easyhaler®, an in-house developed dry-powder inhaler. Orion has developed Easyhaler-adapted dry powder formulations of several well-known generic active substances (salbutamol, beclometasone, budesonide, formoterol) used in the treatment of asthma and COPD. At the moment under development are new combined formulations of budesonide-formoterol, and fluticasone-salmeterol for the treatment of asthma and COPD.
About Orion
Orion is an innovative European R&amp;amp;D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&amp;amp;D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.The Group's net sales in 2010 amounted to approximately EUR 850 million. The Company invested EUR 85 million in research and development. At the end of 2010, the Group had a total of approximately 3,100 employees, of whom 2,450 worked in Finland and 650 in other countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki. For more information visit: www.orion.fi/en&amp;nbsp; 
About Nycomed
Nycomed is a privately owned global pharmaceutical company with a diversified portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC products completes the portfolio.Its R&amp;amp;D is structured around collaborations. In-licensing and expanding in emerging markets are cornerstones of the company's growth strategy.Nycomed employs 12,500 associates worldwide, and its products are sold in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, Latin America, Asia and the Middle East. In the US and Japan its products are available through best in class partners.Headquartered in Zurich, Switzerland, the company generated total sales of € 3.2 billion in 2010 and an adjusted EBITDA of € 851 million.]]></description><pubDate>Thu, 04 Aug 2011 06:35:06 GMT</pubDate><guid>http://www.nycomed.com/media/news-releases/2011/nycomed-and-orion-corporation-to-collaborate-on-easyhaler-for-asthma-and-copd/</guid></item></channel></rss>
